Literature DB >> 8636267

Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity.

F L Hew1, M Koschmann, M Christopher, C Rantzau, A Vaag, G Ward, H Beck-Nielsen, F Alford.   

Abstract

Fourteen GH-deficient (GHD) adults were compared with 12 age-, sex-, and body mass index-matched control subjects using a baseline tritiated glucose equilibration period and euglycemic-hyperinsulinemic (approximately 55 mU/L) clamp in conjunction with paired muscle biopsies for measurement of glycogen synthase fractional velocity (FV0.1). Despite similar basal rates of total glucose disposal (Rd), there was a 64% reduction in the insulin-stimulated rise (delta) in Rd in the GHD adults compared to that in controls [16.6 +/- 2.8 vs. 44.7 +/- 6.0 mumol/kg fat free mass (FFM)/min; P < 0.001], which was mainly due to a decreased glucose storage (GS) rate (delta GS, 12.6 +/- 2.9 vs. 39.5 +/- 7.5 mumol/kg FFM/min; P < 0.01). Furthermore, the insulin sensitivity indexes of Rd (0.39 +/- 0.07 vs. 0.85 +/- 0.11; P < 0.05) and GS (0.25 +/- 0.07 vs. 0.72 +/- 0.13 mumol/kg FFM/min per mU/L; P < 0.02) were reduced in GHD adults compared to the control values. The insulin sensitivity of the glycolytic pathway was also reduced by approximately 50% in GHD adults (P = 0.07 vs. controls). Insulin-stimulated FV0.1 was decreased in GHD adults (0.31 +/- 0.02 vs. 0.47 +/- 0.03; P < 0.005) despite similar basal FV0.1. Using multiple and stepwise regression analysis, duration of GH deficiency, fasting triglycerides and fasting insulin accounted for 67% of the variance in the insulin sensitivity index of Rd. In conclusion, the severe insulin resistance in GHD adults is mainly due to the inhibition of the GS pathway and glycogen synthase activity in peripheral tissues, which is related to the duration of GH deficiency, fasting triglycerides, and fasting insulin.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636267     DOI: 10.1210/jcem.81.2.8636267

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  24 in total

Review 1.  Long-term growth hormone replacement therapy in hypopituitary adults.

Authors:  Johan Verhelst; Roger Abs
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 2.  Effects of GH replacement on metabolism and physical performance in GH deficient adults.

Authors:  S K Abdul Shakoor; S M Shalet
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 3.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

4.  Two years of growth hormone replacement therapy in a group of patients with Sheehan's syndrome.

Authors:  Débora Vieira Soares; Luciana Diniz Carneiro Spina; Rosane Resende de Lima Oliveira Brasil; Priscila Marise Lobo; Elizabeth Salles; Claúdia Medina Coeli; Flávia Lúcia Conceição; Mario Vaisman
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

5.  Effects of growth hormone deficiency on body composition and biomarkers of cardiovascular risk after definitive therapy for acromegaly.

Authors:  E Lin; T L Wexler; L Nachtigall; N Tritos; B Swearingen; L Hemphill; J Loeffler; B M K Biller; A Klibanski; K K Miller
Journal:  Clin Endocrinol (Oxf)       Date:  2012-09       Impact factor: 3.478

6.  Differential impact of selective GH deficiency and endogenous GH excess on insulin-mediated actions in muscle and liver of male mice.

Authors:  Jose Cordoba-Chacon; Manuel D Gahete; Owen P McGuinness; Rhonda D Kineman
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-09-30       Impact factor: 4.310

7.  Growth hormone and the heart in growth hormone deficiency-what have we learned so far?

Authors:  Jörgen Isgaard; Antonio Cittadini
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

8.  A rare case of adulthood-onset growth hormone deficiency presenting as sporadic, symptomatic hypoglycemia.

Authors:  A Pia; A Piovesan; F Tassone; P Razzore; G Visconti; G Magro; F Cesario; M Terzolo; G Borretta
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

9.  Adipokine profile and urinary albumin excretion in isolated growth hormone deficiency.

Authors:  Carla R P Oliveira; Roberto Salvatori; Rafael A Meneguz-Moreno; Manuel H Aguiar-Oliveira; Rossana M C Pereira; Eugênia H A Valença; Vanessa P Araujo; Natália T Farias; Débora C R Silveira; Jose G H Vieira; Jose A S Barreto-Filho
Journal:  J Clin Endocrinol Metab       Date:  2009-12-16       Impact factor: 5.958

10.  Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Authors:  Janet Lo; Sung Min You; Bridget Canavan; James Liebau; Greg Beltrani; Polyxeni Koutkia; Linda Hemphill; Hang Lee; Steven Grinspoon
Journal:  JAMA       Date:  2008-08-06       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.